Cantor Fitzgerald Reiterates Overweight on Janux Therapeutics, Maintains $100 Price Target

Benzinga · 05/09 14:20
Cantor Fitzgerald analyst Josh Schimmer reiterates Janux Therapeutics (NASDAQ:JANX) with a Overweight and maintains $100 price target.